Effective as of March 21, 2016, MetaStat, Inc. and Anthony Shuber entered into a consulting agreement whereby Mr. Shuber will serve as the company's head of diagnostic research and development and shall be responsible for the guidance and oversight of MetaStat's diagnostic research and development efforts. Most recently, Mr. Shuber was vice president and chief scientific officer for Nabsys Inc., where he developed the clinical strategy for the application of structural variation analysis in oncology.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 587 | |
+48.99% | 56.95B | |
+39.98% | 40.26B | |
-6.99% | 39.32B | |
-4.42% | 28.37B | |
+11.82% | 26.45B | |
-17.85% | 19.41B | |
+29.43% | 12.54B | |
+25.24% | 12.21B | |
-0.40% | 12.15B |
- Stock Market
- Equities
- MTST Stock
- News MetaStat, Inc.
- Metastat, Inc. Appoints Anthony Shuber as Head of Diagnostic Research and Development